ANÁLISE PRELIMINAR DO USO DE BIOLÓGICOS NO TRATAMENTO DA ARTRITE REUMATOIDE

Alexia Ribeiro Silva; Guilherme Spezia Dalla Costa; Barbara Stadler Kahlow; Thelma Skare

doi:10.1590/SciELOPreprints.6548

##article.authors##

Alexia Ribeiro Silva Serviço de Reumatologia, Hospital Universitário Evangélico Mackenzie de Curitiba, Curitiba, PR, Brasil.
Guilherme Spezia Dalla Costa Serviço de Reumatologia, Hospital Universitário Evangélico Mackenzie de Curitiba, Curitiba, PR, Brasil.
Barbara Stadler Kahlow Serviço de Reumatologia, Hospital Universitário Evangélico Mackenzie de Curitiba, Curitiba, PR, Brasil.
Thelma Skare Faculdade Evangélica Mackenzie do Paraná https://orcid.org/0000-0002-7699-3542

DOI:

https://doi.org/10.1590/SciELOPreprints.6548

Keywords:

Rheumatoid arthritis, Treatment, Biological drugs

Abstract

Introduction: Rheumatoid arthritis (RA) is treated with conventional and biological disease-modifying drugs (DMARDs). Objectives: To compare the survival of biological drugs used for the treatment of RA patients. Methods: Retrospective study of medical records of patients who used biological medication for the treatment of RA from January 2020 to January 2022 and this was suspended. Data on the causes of withdrawal, duration of use, epidemiological, clinical and comorbid data were collected. Results: The main reason for discontinuity was failure followed by side effects. Infliximab and adalimumab had the highest survival. BMI (body mass index) and smoking, sex and age did not interfere in this survival. Conclusion: Failure is the most common cause of biological discontinuity. Among the factors studied (smoking, BMI, age and gender) it was not possible to identify a variable that was associated with failure.